As much as I agree that HA-I is not getting enough value ascribed to it, I'm not sure about the assumption that HA-I will jump to $500M.
Irinotecan had $900M sales until generics entered the market, so would have dropped back from there. You need to allow for % market penetration, risk of failure, time to market, partnering or production cost, etc.
That said, even if you're 500% optimistic, HA-I still carries significant value not currently recognised by the market. A Phase III trial will push it onto the stage.
As much as I agree that HA-I is not getting enough value...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable